Novartis Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Novartis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count).

1,375 total trials 110 currently recruiting 944 completed early-phase tilt top decile by trial count

Novartis Pharmaceuticals: 1,375 sponsored US clinical trials, 110 recruiting.

Novartis Pharmaceuticals sponsors 1,375 registered US clinical trials on ClinicalTrials.gov, 110 of them currently recruiting, and 944 completed. 470 of these trials are in Phase 3-4 (later-stage) and 776 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 10 trials.

Top-decile sponsor footprint

Novartis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

944 of 1,179 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,375 total, page 18 of 28

COMPLETED

Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis

NCT02907281
COMPLETED Phase 3

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

NCT01555125
COMPLETED Phase 3

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

NCT01584648
COMPLETED Phase 1

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

NCT01558323
COMPLETED Phase 1

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors

NCT01596647
COMPLETED Phase 1

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01456689
COMPLETED Phase 2

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
COMPLETED Phase 1

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

NCT01468688
COMPLETED Phase 2

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491529
COMPLETED Phase 4

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

NCT01570686
COMPLETED Phase 1

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

NCT01594957
TERMINATED Phase 2

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

NCT01528345
COMPLETED Phase 3

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)

NCT01524783
TERMINATED Phase 2

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

NCT01562041
COMPLETED Phase 1

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

NCT01487785
COMPLETED Phase 1

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

NCT01482143
COMPLETED Phase 2

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

NCT01520922
COMPLETED Phase 2

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932
COMPLETED Phase 1

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332
COMPLETED Phase 1

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

NCT01324479
COMPLETED Phase 2

Continuation Study of the Oral AKT Inhibitor GSK2110183

NCT01531894
COMPLETED Phase 2

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

NCT01479595
COMPLETED Phase 2

Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)

NCT01546532
COMPLETED Phase 2

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950
COMPLETED Phase 2

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

NCT01527500
COMPLETED Phase 1

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

NCT01474681
COMPLETED Phase 2

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

NCT01537432
COMPLETED Phase 2

A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

NCT01601600
COMPLETED Phase 4

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

NCT01519661
COMPLETED Phase 4

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01543828
COMPLETED Phase 1

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

NCT01482156
COMPLETED Phase 2

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

NCT01337752
COMPLETED Phase 1

A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT01473901
COMPLETED Phase 1

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

NCT01430416
COMPLETED Phase 1

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

NCT01351103
COMPLETED Phase 3

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

NCT01412944
COMPLETED Phase 1

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

NCT01421004
TERMINATED Phase 2

Efficacy of LCQ908 on Cardiovascular Risk

NCT01474434
COMPLETED Phase 3

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

NCT01374906
COMPLETED Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

NCT01487460
COMPLETED Phase 2

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

NCT01491672
COMPLETED Phase 2

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

NCT01379534
COMPLETED Phase 2

Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01385592
COMPLETED Phase 3

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

NCT01470989
COMPLETED Phase 1

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

NCT01443481
TERMINATED Phase 2

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

NCT01402401
TERMINATED Phase 1

Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma

NCT01402440
TERMINATED Phase 2

Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

NCT01433354
COMPLETED

The Gilenya Pregnancy Registry

NCT01285479
COMPLETED Phase 2

Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis Taking Methotrexate

NCT01359943
← Previous Page 18 of 28 Next →

Phase Distribution

PhaseTrial count
Phase 1 326
Phase 2 450
Phase 3 393
Phase 4 77

Therapeutic Areas

Non-Small Cell Lung Cancer 10
Breast Cancer 9
Multiple Sclerosis 9
Chronic Spontaneous Urticaria 8
Hypertension 7
Melanoma 7
Relapsing Multiple Sclerosis 6
Carcinoma, Non-Small Cell Lung 6
Hidradenitis Suppurativa 5
Sickle Cell Disease 5

What is open in the Novartis Pharmaceuticals pipeline

110 recruiting of 1,375 indexed (8% open); 944 completed (69%).

Phase mix: 470 late (III/IV) vs 776 early (I/II) (early-phase heavy).

Top condition: Non-Small Cell Lung Cancer (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Novartis Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 1,375 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 0%5%10%15% Total trials Recruiting share Novartis PharmaceuticalsGlaxoSmithKlineEli Lilly and CompanyUniversity of PennsylvaniaUniversity of MichiganArcutis BiotherapeuticsMedtronic EndovascularPenumbraSK Life Science
Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,375 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Novartis Pharmaceuticals page

1,375 registered trials is a research-attention snapshot, not an endorsement of Novartis Pharmaceuticals or any single study.

  • 110 of Novartis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-Small Cell Lung Cancer is the condition Novartis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novartis Pharmaceuticals pipeline card: 1,375 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.